FindTrial
Sign In

An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease

An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease - An evaluation of the safety of inosine for patients with Parkinson's disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009062
Enrollment
20
Registered
2012-10-09
Start date
2016-05-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL

Sponsors

Dept. of Clinical pharmacology and Neurology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: * Diagnosed with Parkinson's disease according to UK Parkinson's Disease Society Brain Bank criteria * Baseline serum UA below 5.5(male) or 4.2 (female) * Age 20 or older at the time of enrolment

Exclusion criteria

Exclusion criteria: * History of kidney stones, gout (or other arthritis), or ischemic heart diseases * History of any kidney diseases or baseline eGFR below 60 (mL/min/1.73 m2) * Acidic urine (pH<5.0), uric acid or uric salt crystal in urine test * Blood pressure >160/80 mmHg or unstable hypertension * Use of certain medication including diuretics, losartan, antituberculosis drugs, or immune suppressors * Use of daily NSAIDs * Woman who are pregnant or lactating * Other inadequate status for clinical trial

Design outcomes

Primary

MeasureTime frame
The safety of using inosine to elevate serum UA level—

Secondary

MeasureTime frame
The degree to which the serum UA level can be increased The capacity to maintain a target range UA level The change in UPDRS/Yahr The period before starting/increasing L-dopa—

Countries

Japan

Contacts

Public ContactHirotaka Iwaki

Ehime University Dept. of Clinical pharmacology and Neurology

h-iwaki@m.ehime-u.ac.jp089-960-5095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026